Historical Valuation
Urogen Pharma Ltd (URGN) is now in the Fair zone, suggesting that its current forward PS ratio of 5.26 is considered Fairly compared with the five-year average of -4.31. The fair price of Urogen Pharma Ltd (URGN) is between 18.68 to 30.53 according to relative valuation methord.
Relative Value
Fair Zone
18.68-30.53
Current Price：21.25
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Urogen Pharma Ltd (URGN) has a current Price-to-Book (P/B) ratio of -9.21. Compared to its 3-year average P/B ratio of -3.63 , the current P/B ratio is approximately 153.85% higher. Relative to its 5-year average P/B ratio of -0.66, the current P/B ratio is about 1291.84% higher. Urogen Pharma Ltd (URGN) has a Forward Free Cash Flow (FCF) yield of approximately -12.99%. Compared to its 3-year average FCF yield of -21.54%, the current FCF yield is approximately -39.67% lower. Relative to its 5-year average FCF yield of -27.83% , the current FCF yield is about -53.31% lower.
P/B
Median3y
-3.63
Median5y
-0.66
FCF Yield
Median3y
-21.54
Median5y
-27.83
Competitors Valuation Multiple
AI Analysis for URGN
The average P/S ratio for URGN competitors is 11.57, providing a benchmark for relative valuation. Urogen Pharma Ltd Corp (URGN.O) exhibits a P/S ratio of 5.26, which is -54.58% above the industry average. Given its robust revenue growth of 9.04%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for URGN
1Y
3Y
5Y
Market capitalization of URGN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of URGN in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is URGN currently overvalued or undervalued?
Urogen Pharma Ltd (URGN) is now in the Fair zone, suggesting that its current forward PS ratio of 5.26 is considered Fairly compared with the five-year average of -4.31. The fair price of Urogen Pharma Ltd (URGN) is between 18.68 to 30.53 according to relative valuation methord.
What is Urogen Pharma Ltd (URGN) fair value?
URGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Urogen Pharma Ltd (URGN) is between 18.68 to 30.53 according to relative valuation methord.
How does URGN's valuation metrics compare to the industry average?
The average P/S ratio for URGN's competitors is 11.57, providing a benchmark for relative valuation. Urogen Pharma Ltd Corp (URGN) exhibits a P/S ratio of 5.26, which is -54.58% above the industry average. Given its robust revenue growth of 9.04%, this premium appears unsustainable.
What is the current P/B ratio for Urogen Pharma Ltd (URGN) as of Jan 10 2026?
As of Jan 10 2026, Urogen Pharma Ltd (URGN) has a P/B ratio of -9.21. This indicates that the market values URGN at -9.21 times its book value.
What is the current FCF Yield for Urogen Pharma Ltd (URGN) as of Jan 10 2026?
As of Jan 10 2026, Urogen Pharma Ltd (URGN) has a FCF Yield of -12.99%. This means that for every dollar of Urogen Pharma Ltd’s market capitalization, the company generates -12.99 cents in free cash flow.
What is the current Forward P/E ratio for Urogen Pharma Ltd (URGN) as of Jan 10 2026?
As of Jan 10 2026, Urogen Pharma Ltd (URGN) has a Forward P/E ratio of -14.68. This means the market is willing to pay $-14.68 for every dollar of Urogen Pharma Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Urogen Pharma Ltd (URGN) as of Jan 10 2026?
As of Jan 10 2026, Urogen Pharma Ltd (URGN) has a Forward P/S ratio of 5.26. This means the market is valuing URGN at $5.26 for every dollar of expected revenue over the next 12 months.